CN1285836A - 3′－差向异构的K－252a衍生物 - Google Patents

3′－差向异构的K－252a衍生物 Download PDF

Info

Publication number
CN1285836A
CN1285836A CN98812812A CN98812812A CN1285836A CN 1285836 A CN1285836 A CN 1285836A CN 98812812 A CN98812812 A CN 98812812A CN 98812812 A CN98812812 A CN 98812812A CN 1285836 A CN1285836 A CN 1285836A
Authority
CN
China
Prior art keywords
hydrogen
unsubstituted
aryl
replacement
alkyl group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN98812812A
Other languages
English (en)
Chinese (zh)
Inventor
罗伯特·L·赫德金斯
黛安娜·E·金里奇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KH Neochem Co Ltd
Cephalon LLC
Original Assignee
Kyowa Hakko Kogyo Co Ltd
Cephalon LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyowa Hakko Kogyo Co Ltd, Cephalon LLC filed Critical Kyowa Hakko Kogyo Co Ltd
Publication of CN1285836A publication Critical patent/CN1285836A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
CN98812812A 1997-12-31 1998-12-30 3′－差向异构的K－252a衍生物 Pending CN1285836A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7026397P 1997-12-31 1997-12-31
US60/070,263 1997-12-31

Publications (1)

Publication Number Publication Date
CN1285836A true CN1285836A (zh) 2001-02-28

Family

ID=22094212

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98812812A Pending CN1285836A (zh) 1997-12-31 1998-12-30 3′－差向异构的K－252a衍生物

Country Status (15)

Country Link
US (2) US6093713A (enExample)
EP (1) EP1044203B1 (enExample)
JP (1) JP4405667B2 (enExample)
KR (1) KR20010033737A (enExample)
CN (1) CN1285836A (enExample)
AT (1) ATE234308T1 (enExample)
AU (1) AU1947499A (enExample)
BR (1) BR9814543A (enExample)
CA (1) CA2315953C (enExample)
DE (1) DE69812177T2 (enExample)
DK (1) DK1044203T3 (enExample)
ES (1) ES2194385T3 (enExample)
NO (1) NO20003397L (enExample)
PT (1) PT1044203E (enExample)
WO (1) WO1999033836A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2275373C2 (ru) * 2000-12-08 2006-04-27 Орто-Макнейл Фармасьютикал, Инк. Макрогетероциклические соединения
US7018999B2 (en) 2001-05-16 2006-03-28 Cephalon, Inc. Methods for the treatment and prevention of pain
DE60212836T2 (de) * 2001-05-16 2007-01-25 Gpc Biotech Ag Pyridylpyrimidin-derivate als wirksame verbindungen gegen prionen-krankheiten
DE10161940A1 (de) * 2001-12-17 2003-07-03 Nad Ag N-Carbacyclus-monosubstitutierte Indolocarbazole als Proteinkinase-inhibitoren
US6723844B1 (en) * 2003-02-27 2004-04-20 Abbott Laboratories Preparation of K-252a
DE102004025726B4 (de) * 2004-05-26 2006-07-06 Roder, Hanno, Dr. Verwendung eines spezifischen K252a-Derivats zur Verhinderung oder Behandlung der Alzheimerschen Krankheit
US20060058250A1 (en) * 2004-09-10 2006-03-16 Cephalon, Inc. Methods of treating proliferative skin diseases using carbazole derivatives
US20080021013A1 (en) * 2006-07-21 2008-01-24 Cephalon, Inc. JAK inhibitors for treatment of myeloproliferative disorders
EP2124554B1 (en) * 2006-12-14 2012-02-08 Tautatis, Inc. Compositions and methods for the treatment of cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62155284A (ja) * 1985-12-27 1987-07-10 Kyowa Hakko Kogyo Co Ltd 生理活性物質ｋ−２５２の誘導体
JPH0826036B2 (ja) 1987-01-22 1996-03-13 協和醗酵工業株式会社 生理活性物質ｋ−２５２の誘導体
WO1988007045A1 (fr) * 1987-03-09 1988-09-22 Kyowa Hakko Kogyo Co., Ltd. Derives de la substance physiologiquement active k-252
US5621100A (en) * 1992-07-24 1997-04-15 Cephalon, Inc. K-252a derivatives for treatment of neurological disorders
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
WO1994027982A1 (en) 1993-05-28 1994-12-08 Cephalon, Inc. Use of indolocarbazole derivatives to treat a pathological condition of the prostate
US5468872A (en) * 1993-09-16 1995-11-21 Cephalon, Inc. K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
US5585488A (en) * 1994-07-04 1996-12-17 Kyowa Hakko Kogyo Co., Ltd. Process for producing indolocarbazole derivatives
WO1997005140A1 (en) 1995-07-31 1997-02-13 Novartis Ag Trindene compounds
WO1997007081A2 (en) 1995-08-11 1997-02-27 Yale University Glycosylated indolocarbazole synthesis

Also Published As

Publication number Publication date
NO20003397L (no) 2000-08-31
DE69812177T2 (de) 2004-01-15
AU1947499A (en) 1999-07-19
US6093713A (en) 2000-07-25
CA2315953C (en) 2010-11-09
WO1999033836A1 (en) 1999-07-08
JP2001527079A (ja) 2001-12-25
PT1044203E (pt) 2003-07-31
KR20010033737A (ko) 2001-04-25
ES2194385T3 (es) 2003-11-16
WO1999033836A9 (en) 2000-09-14
DK1044203T3 (da) 2003-07-14
NO20003397D0 (no) 2000-06-29
JP4405667B2 (ja) 2010-01-27
CA2315953A1 (en) 1999-07-08
ATE234308T1 (de) 2003-03-15
EP1044203B1 (en) 2003-03-12
EP1044203A1 (en) 2000-10-18
BR9814543A (pt) 2000-10-10
DE69812177D1 (de) 2003-04-17
US6451786B1 (en) 2002-09-17

Similar Documents

Publication Publication Date Title
CN1449287A (zh) 具有抗炎作用的稠合吡咯并咔唑
CN1304311A (zh) 桥连的茚并吡咯并咔唑
CN107089985A (zh) 作为詹纳斯相关激酶(jak)抑制剂的吡咯并[2,3‑d]嘧啶衍生物
JP2001519412A (ja) Ｃｃ−１０６５およびデュオカルマイシンのイソ−ｃｂｉおよびイソ−ｃｉ類似体
CN1219841A (zh) 作为抗肿瘤剂的结合dna的吲哚衍生物,前药及其免疫轭合物
CN106084002A (zh) 杂交环状文库和其筛选
JP5006046B2 (ja) 新規な縮合ピロロカルバゾール
CN104736534A (zh) 用于治疗糖尿病及其相关紊乱症的2-苯基-5-杂环基-四氢-2h-吡喃-3-胺化合物
CN101679444A (zh) 具有正变构gabab受体调节剂作用的黄嘌呤化合物
CN1087910A (zh) 5-取代的吡咯并[2，3-d]嘧啶的制备方法
WO2015085844A1 (zh) 作为抗病毒剂的咪唑衍生物及其制药用途
WO2022135610A1 (zh) 四并环化合物及其药物组合物和应用
CA2315953C (en) 3'-epimeric k-252a derivatives
US20240083875A1 (en) Dihydroisoquinolinyl derivatives
CN1301255C (zh) αLβ2整合素介导的细胞粘附抑制剂
CN1139573C (zh) 稠合异吲哚酮作为蛋白激酶c抑制剂
US20150232473A1 (en) Novel gabaa agonists and methods of using to control airway hyperresponsiveness and inflammation in asthma
KR20200092946A (ko) 결정질 리나글립틴 중간체 및 리나글립틴 제조 공정
WO2014096093A1 (fr) 3,5-diaryl-azaindoles comme inhibiteurs de la protéine dyrk1a pour le traitement des déficiences cognitives liées au syndrome de down et à la maladie d'alzheimer
RU2441876C2 (ru) Производное 3'-этинилцитидина
MXPA00006500A (en) 3'-epimeric k-252a derivatives
AU2001285205B2 (en) Fused pyrrolocarbazoles against inflammation
AU2001285205A1 (en) Fused pyrrolocarbazoles against inflammation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication